BioMarin Pharmaceutical Inc. BMRN was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $83.50 to $89.87 in the past one-month time frame.
The upmove came after the company announced that the FDA has accepted valoctocogene roxaparvovec under priority review. Notably, the drug is being developed to treat adults with hemophilia A.
The company has seen one negative estimate revision in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
BioMarin currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
BioMarin Pharmaceutical Inc. Price
BioMarin Pharmaceutical Inc. price | BioMarin Pharmaceutical Inc. Quote
Investors interested in the Medical - Biomedical and Genetics industry may consider Guardant Health, Inc. GH, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is BMRN going up? Or down? Predict to see what others think:Up or Down
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.7% per year.
These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
BioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
Guardant Health, Inc. (GH) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research